好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Surface Modification in Flow Diverters for the Embolization of Intracranial Aneurysms: A Comparative Analysis
Cerebrovascular Disease and Interventional Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
4-007

We conducted a systematic review and meta-analysis to evaluate the angiographic and periprocedural outcomes for embolization with Flow diverters (FDs) with surface modification (SM).

Flow diverters (FDs) with surface modification (SM) have been developed to reduce thromboembolic complications in patients undergoing embolization of intracranial aneurysms. However, large-scale analyses of head-to-head comparisons of SM-FD and non-SM-FD are lacking. 

A literature search was performed across PubMed, Embase, and Cochrane databases from inception to July 2025 to identify studies comparing SM-FDs and non-SM-FDs. Outcomes of interest included periprocedural thromboembolic and hemorrhagic complications, as well as adequate and complete aneurysm occlusion rates at follow-up intervals. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model.

Nine studies, comprising 2,332 patients (SM-FDs:783, non-SM-FDs:1,549), were included. Risks of periprocedural thromboembolic or ischemic complications were lower in the SM-FD group (RR:0.44; CI:0.22-0.87; p=0.019). However, no significant difference was observed for periprocedural hemorrhagic complications (RR:0.74; CI:0.26-2.16; p=0.587). There were no statistically significant differences observed at any follow-up interval (immediate, at 6, and 12 months) in the unadjusted primary analyses of adequate and complete aneurysm occlusion. However, SM-FDs were found to have significantly higher rates of adequate (RR: 1.31; CI: 1.08-1.59; p = 0.006) and complete (RR: 1.20; CI: 1.05-1.36; p = 0.006) occlusion at 6-month follow-up in sensitivity analyses to limit heterogeneity.

Our findings in this large meta-analysis of studies making head-to-head comparisons support the efficacy of SM-FDs in reducing thromboembolic complications. Further prospective studies with more granular design are warranted to confirm these findings.

Authors/Disclosures
Lee Wei Jun, MBBS
PRESENTER
Dr. Wei Jun has nothing to disclose.
Rafaela Correia Maciel Miss Correia Maciel has nothing to disclose.
Natan L. Lima, MB Mr. Lima has nothing to disclose.
Mariana Letícia d. Maximiano, MD Dr. Maximiano has nothing to disclose.
Tam Q. Tran, MD Dr. Tran has nothing to disclose.
Aishwarya Koppanatham, MBBS Ms. Koppanatham has nothing to disclose.
Pichatorn Suppakitjanusant, MD (Texas Tech University Health Sciences) Pichatorn Suppakitjanusant, MD has nothing to disclose.
Adam Dmytriw (Massachusetts General Hospital) Adam Dmytriw has nothing to disclose.
Michael Nahhas, MD (UTHealth Neurosciences Houston - Texas Medical Center) Dr. Nahhas has nothing to disclose.
Sunil Sheth, MD (University of Texas At Houston) Dr. Sheth has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Penumbra. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imperative Care.
Robert W. Regenhardt, MD, PhD Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.